middle.news
How Cyclopharm’s US Technegas Surge is Reshaping Its Growth Trajectory
8:02pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How Cyclopharm’s US Technegas Surge is Reshaping Its Growth Trajectory
8:02pm on Wednesday 25th of February, 2026 AEDT
Key Points
Record group revenue of $32.3 million, up 17% year-on-year
US Technegas revenue soared 226% to $2.7 million, becoming largest individual market
Third-party distribution revenue grew 26% to $15.6 million
Net loss widened to $17.2 million due to targeted US market investments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CYCLOPHARM (ASX:CYC)
OPEN ARTICLE